Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan

被引:12
作者
Liu, CY
Chiu, NY
Wu, CK
Yuan, LM
Hsiao, MC
Liao, O
机构
[1] Linkou & Chang Gung Univ, Dept Psychiat, Chang Gung Mem Hosp, Tao Yuan 333, Taiwan
[2] Chang Hua Christian Hosp, Dept Psychiat, Changhua, Taiwan
[3] Chang Gung Mem Hosp, Dept Psychiat, Kaohsiung, Taiwan
[4] Wei Gong Mem Hosp, Dept Psychiat, Miaoli, Taiwan
关键词
atypical antipsychotic; atypical neuroleptic; dose;
D O I
10.1097/00004850-200301000-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres. Only stable patients maintained on a medication at a dose that had remained unchanged for more than I month were included in the analysis. Of the 268 cases, 175 were treated with risperidone and 93 with olanzapine at mean daily doses of 3.56 +/- 1.54 mg and 12.21 +/- 4.99 mg, respectively. The majority of the risperidone-treated patients (73.2%) received 2-4 mg per day, with another 19.0% receiving 5-6 mg. A daily dose of 10-20 mg was received by 82.9% of the olanzapine group. Although the mean daily doses for both drugs were slightly higher for inpatients than outpatients, statistical significance was not achieved. Further, no gender or age-group dose differences were demonstrated for either drug. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:49 / 51
页数:3
相关论文
共 12 条
[1]   Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia [J].
Barnes, TRE ;
McPhillips, MA .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 :S49-S57
[2]   A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder [J].
Conley, RR ;
Mahmoud, R .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (05) :765-774
[3]   Olanzapine - A pharmacoeconomic review of its use in schizophrenia [J].
Foster, RH ;
Goa, KL .
PHARMACOECONOMICS, 1999, 15 (06) :611-640
[4]   Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study [J].
Kasper, S ;
Rosillon, D ;
Duchesne, I .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) :179-187
[5]   Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia [J].
Kasper, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (06) :253-262
[6]   Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response [J].
Labelle, A ;
Light, M ;
Dunbar, F .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 (06) :534-541
[7]  
Lin Keh-Ming, 1995, P1907
[8]  
LIN KM, 1991, PSYCHOPHARMACOL BULL, V27, P427
[9]   Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial [J].
Perry, PJ ;
Lund, BC ;
Sanger, T ;
Besley, C .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (01) :14-20
[10]   Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine [J].
Procyshyn, RM ;
Zerjav, S .
CLINICAL THERAPEUTICS, 1998, 20 (06) :1203-1217